Skip to content
Screener

Repligen RGEN Q4 2025 Annual earnings

Reported February 24, 2026 · Before market open

Revenue$197.9MBeat by $5.0M
EPS$0.49Beat by $0.05
Revenue estimate$192.9M
EPS estimate$0.44

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$206.8M
EPS estimate$0.46

Financials

Q4 2025

Income statement

See full
Net income$13.3M+139%

Balance sheet

See full
Cash & equivalents$566.0M-25.3%
Total debt$689.9M+0.5%
Total equity$2.1B+6.8%
Total assets$2.9B+4.2%

Cash flow

See full
Operating cash flow$25.7M-34.4%
CapEx$8.2M+47.2%
Free cash flow$17.6M-47.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$9.22B+14.4%
Enterprise value$9.35B+16.9%
P/E188.6×—

Returns & leverage

See full
Return on equity2.4%+1.7pp
Debt / equity0.3×0.0×
Current ratio8.4×0.0×

Segments

By product

See full
Proteins Products$24.4M+30.9%
Process Analytics Products$20.3M+37.0%

FAQ

When did Repligen report Q4 2025 earnings?
Repligen (RGEN) reported Q4 2025 earnings on February 24, 2026 before market open.
What were Repligen's Q4 2025 revenue and EPS?
Repligen reported revenue of $197.9M and eps of $0.49 for Q4 2025.
Did Repligen beat estimates in Q4 2025?
Revenue beat the consensus estimate of $192.9M by $5.0M. EPS beat the consensus estimate of $0.44 by $0.05.
How did Repligen's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.1% from $167.5M a year earlier and eps grew 11.4% from $0.44.
Where can I find Repligen's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-065246) and the 10-K periodic report (0001193125-26-076528) directly on SEC EDGAR. The filing index links above go to sec.gov.